HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Azacitidine (5 Azacytidine)

A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Also Known As:
5 Azacytidine; Vidaza; 5-Azacytidine; Azacytidine; NSC-102816; NSC 102816; NSC102816; 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-
Networked: 2073 relevant articles (224 outcomes, 366 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Fenaux, Pierre: 60 articles (01/2022 - 12/2005)
2. Garcia-Manero, Guillermo: 52 articles (12/2022 - 07/2007)
3. Santini, Valeria: 33 articles (01/2022 - 03/2009)
4. Gore, Steven D: 30 articles (01/2020 - 03/2009)
5. Beach, C L: 27 articles (12/2022 - 05/2005)
6. Kantarjian, Hagop M: 25 articles (01/2022 - 05/2002)
7. Zeidan, Amer M: 23 articles (12/2022 - 06/2013)
8. Voso, Maria Teresa: 22 articles (12/2022 - 10/2003)
9. Silverman, Lewis R: 21 articles (12/2022 - 05/2002)
10. Ravandi, Farhad: 21 articles (01/2022 - 10/2007)

Related Diseases

1. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
2. Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/01/2018 - "In this prospective trial, the efficacy of azacitidine in lower-risk myelodysplastic syndromes (LR-SMD) lacking del(5q) was compared to best supportive care (BSC) at 1:1. The primary endpoint was the achievement of erythroid hematologic improvement (HI-E) after nine cycles. "
11/01/2010 - "The earliest and the most successful epigenetic drug to date, 5-Azacytidine, is currently recommended as the first-line treatment of high-risk myelodysplastic syndromes (MDS). "
07/01/2013 - "These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain complete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial remission."
01/01/2013 - "Around 6 weeks after this single azacitidine cycle, complete remission-according to international working group criteria-was observed with continuous improvement in peripheral blood counts to normal values, transfusion-independence, normal blast count (< 5 %) with normal morphology and flow cytometry, as well as a normal bone marrow karyotype and no dysplastic stigmata suggestive of a coexisting myelodysplastic syndrome. "
11/01/2010 - "Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. "
3. Leukemia
4. Neoplasms (Cancer)
5. Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)

Related Drugs and Biologics

1. venetoclax
2. Decitabine
3. Cytarabine (Cytosar-U)
4. DNA (Deoxyribonucleic Acid)
5. Lenalidomide (CC 5013)
6. Methyltransferases
7. cc-486
8. Nucleosides
9. Vorinostat
10. Histone Deacetylase Inhibitors

Related Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Induction Chemotherapy
4. Hematopoietic Stem Cell Transplantation
5. Transplantation